0102030405
Abaloparatide Anabolic Treatment for Osteoporosis
Detailed Description
Abaloparatide, marketed under the brand name Tymlos, is a synthetic analog of parathyroid hormone-related protein (PTHrP). It is an anabolic agent used to treat osteoporosis, a condition characterized by weakened bones and an increased risk of fractures. Abaloparatide is indicated for postmenopausal women and men with osteoporosis at high risk for fracture, as well as for those who have failed or are intolerant to other available osteoporosis therapies. By selectively activating the parathyroid hormone 1 receptor (PTH1R), abaloparatide promotes bone growth and increases bone density.
Abaloparatide is a 34 amino acid synthetic analog of PTHrP, with 41% homology to parathyroid hormone (PTH) (1-34) and 76% homology to PTHrP (1-34). Its mechanism of action involves binding to the PTH1R, a G protein-coupled receptor expressed in osteoblasts and osteocytes. By preferentially binding to the RG conformational state of the PTH1R, abaloparatide elicits a transient downstream cyclic AMP signaling response, leading to an anabolic signaling pathway.
In postmenopausal women with osteoporosis at high risk for fracture, abaloparatide is an effective treatment option. It helps increase bone mass and reduce the risk of fractures. Additionally, abaloparatide can be used to increase bone density in men with primary or hypogonadal osteoporosis who are at high risk for fracture or have failed or are intolerant to other available therapies.
Furthermore, abaloparatide offers benefits for both men and women with osteoporosis associated with sustained systemic glucocorticoid therapy. These individuals are at high risk for fractures due to the long-term use of glucocorticoids. Abaloparatide can help improve bone strength and reduce fracture risk in this specific population.
Abaloparatide, a synthetic analog of PTHrP, is a valuable treatment for osteoporosis. Its anabolic properties promote bone growth and increase bone density, reducing the risk of fractures. It is indicated for postmenopausal women and men at high risk for fracture, as well as for individuals who have failed or are intolerant to other osteoporosis therapies. By selectively activating the PTH1R, abaloparatide triggers an anabolic signaling pathway that enhances bone health. Its use in osteoporosis associated with sustained systemic glucocorticoid therapy provides an important treatment option for individuals at high risk for fractures. Abaloparatide plays a significant role in addressing the needs of patients with osteoporosis and improving their bone health and quality of life.
Specification
